SCHEMBL7013841

SCHEMBL7013841

CCOP(C)(=O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439327 0.79
SCHEMBL18309148 0.77
SCHEMBL575282 0.77
SCHEMBL282085 0.74 TSHR (0.60)
SCHEMBL24052953 0.72
SCHEMBL16785847 0.72 TSHR (0.48)
SCHEMBL575221 0.72
SCHEMBL8764678 0.72
Hydrochloric Acid SCHEMBL9329340 0.72 TSHR (0.57)
Hydrochloric Acid SCHEMBL9004772 0.72 TSHR (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9408840-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder ARDELYX, INC. (US) 2016-08-09 US disclosed
US-20150190389-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER ARDELYX, INC. (US) 2015-07-09 US disclosed
US-9006281-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2015-04-14 US disclosed
US-8969377-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2015-03-03 US disclosed
US-20140107074-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2014-04-17 US disclosed
US-8541448-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2013-09-24 US disclosed
US-20120263670-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2012-10-18 US disclosed
US-20110263870-A1 NOVEL PYRROLE DERIVATIVES AND THEIR SYNTHESIS HELVETICA INDUSTRIES (P) LIMITED (IN) 2011-10-27 US disclosed
US-20030144249-A1 Use of organophosphorous compounds for producing a medicament for treating infections JOMAA PHARMAKA GMBH (DE) 2003-07-31 US disclosed
EP-1272198-A1 USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING A MEDICAMENT FOR TREATING INFECTIONS Jomaa Pharmaka GmbH (DE) 2003-01-08 EP disclosed
WO-2001070237-A1 USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING A MEDICAMENT FOR TREATING INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-09-27 WO disclosed
CN-1004757-B Process for producing alpha-aminoalkylphosphonic acid and alpha-aminoalkylphosphinic acid 赫彻斯特股份公司 1989-07-12 CN disclosed